沈陽藥科大學(xué)制藥工程學(xué)院導(dǎo)師：趙燕芳 正文

[導(dǎo)師姓名]
趙燕芳

[所屬院校]
沈陽藥科大學(xué)

[基本信息]
導(dǎo)師姓名：趙燕芳
性別：女
人氣指數(shù)：838
所屬院校：沈陽藥科大學(xué)
所屬院系：制藥工程學(xué)院
職稱：教授
導(dǎo)師類型：碩導(dǎo)/博導(dǎo)
招生專業(yè)：藥物化學(xué)、藥學(xué)（藥物化學(xué)方向）
研究領(lǐng)域：研究方向一：抗耐藥菌感染創(chuàng)新藥物的研究;研究方向二：小分子靶向抗腫瘤藥物的研發(fā);研究方向三...

[通訊方式]
辦公電話：024-43520216
電子郵件：yanfangzhao@126.com
通訊地址：遼寧省本溪高新技術(shù)產(chǎn)業(yè)開發(fā)區(qū)華佗大街26號(hào)

[個(gè)人簡(jiǎn)述]
趙燕芳，女，博士，教授。1995年畢業(yè)于河北醫(yī)科大學(xué)藥學(xué)院，獲藥學(xué)學(xué)士學(xué)位；2001年獲得沈陽藥科大學(xué)藥物化學(xué)碩士學(xué)位，2004年獲同校藥物化學(xué)博士學(xué)位，同年留校任教。2015年12月被聘為沈陽藥科大學(xué)教授?，F(xiàn)任制藥工程學(xué)院副院長(zhǎng)。作為課題負(fù)責(zé)人，共主持縱向項(xiàng)目5項(xiàng)：包括國(guó)家自然基金青年科學(xué)基金2項(xiàng)；國(guó)家重大新藥創(chuàng)制科技重大專項(xiàng)1項(xiàng)，遼寧省重大新藥創(chuàng)制綜合平臺(tái)子課題1項(xiàng)以及省級(jí)項(xiàng)目3項(xiàng)和沈陽市科技項(xiàng)目2項(xiàng)。共申請(qǐng)發(fā)明專利23項(xiàng)，其中申請(qǐng)PCT 7項(xiàng),獲得授權(quán)4項(xiàng)。發(fā)表研究論文35篇，其中SCI收載20余篇。2015年被評(píng)為遼寧省第九批“百千萬人才工程”百人層次人選。2015年被評(píng)為沈陽藥科大學(xué)優(yōu)秀研究生導(dǎo)師。

[科研工作]
近年來發(fā)表代表性論文
1. Hu, J, Kong B, Liu Y, Xu B, Zhao Y* Gong P* Highly Stereoselective Synthesis of Imidazolidines through the Palladium(0)-Catalyzed Three-Component Reaction of 2,3-Allenylamines, Organic Halides, and Imines. ChemCatChem, 2017, 9, 403-406. DOI: 10.1002/CCTC.201601345.(IF= 4.724)2. Xu B, Zhao Y, Wang X, Gong P* Ge W.* MZH29 is a Novel Potent Inhibitor that Overcomes Drug Resistance FLT3 Mutations in Acute Myeloid Leukemia. Leukemia, 2016, 1–9. (并列第一，IF=12.104)3. Liu M, Hou Y, Yin W, Zhou S, Qian P, Guo Z, Xu LY, Zhao Y.* Discovery of a Novel 6,7-Disubstituted-4-(2-fluorophenoxy)quinolines Bearing 1,2,3-Triazole-4-carboxamide Moiety as Potent c-Met Dinase Inhibitors. European J of Med Chem, 2016, 119, 96-108. DOI: 10.1016 /j.ejmech.2016.04.035(IF=3.902)4. Zhao Y Jiang M, Zhou S, Wu S, Zhang X, Ma L, Zhang K, Ping Gong*. Design, synthesis and Structure Activity Relationship of Oxazolidinone Derivatives Containing Novel S4 Ligand as FXa Inhibitors. European J of Med Chem, 2015, 96, 369-380(第一作者，IF=3.447)5. Wang F, Liu Z, Wang J, Tao J, Gong P, Bao X, Zhao Y*, Wang Y*. The interaction of 4-thiazolidinone derivatives containing indolin-2-one moiety with P-glycoprotein studied using K562 cell lines. European Journal of Medicinal Chemistry, 2015, 101, 126-132(雙通訊,IF=3.447)6. Qin M, Wang T, Xu B, Ma Z, Jiang N, Xie H, Gong P*, Zhao Y*. Novel Hydrazone Moiety-bearing Aminopyrimidines as Selective Inhibitors of Epidermal Growth Factor Receptor T790M Mutant. European J Med Chem, 2015(4): 115-126(雙通訊, IF=3.447)7. Liu Z, Wu S, Wang Y, Li R, Wang J, Wang L, Zhao Y*, Gong P*. Design, Synthesis and Biological Evaluation of Novel Thieno[3,2-d]pyrimidine Derivatives Possessing Diaryl Semicarbazone Scaffolds as Potent Antitumor Agents. European Journal of Medicinal Chemistry, 2014, 87: 782-793(雙通訊, IF=3.432)8. Wang D, Zhao Y, Liu Z, Lei H, Dong M, Gong P*. In vitro and Intracellular Activity of 4-Substituted Piperazinyl Phenyl Oxazolidinone Analogues against Mycobacterium Tuberculosis. J Antimicrob Chemother, 2014, 12, 1711-1714（并列第一作者，IF=5.338）9. Tang Q, Zhang G, Du X, Zhu W, Li R, Lin H, Li P, Cheng M, Gong P, Zhao Y*. Discovery of Novel 6,7-Disubstituted-4-Phenoxy Quinoline Derivatives Bearing 5-(Aminomethylene) pyrimidine-2,4,6-trione Moiety as c-Met Kinase Inhibitors. Bioorganic & Medicinal Chemistry, 2014(22), 1236-1249. (通訊, IF=2.951)10. Zhou S, Liao H, Liu, Feng Guo, Fu B, Li R, Cheng M, Zhao Y*, Gong P*. Discovery and Biological Evaluation of Novel 6,7-Disubstituted-4-(2-fluorophenoxy)quinoline Derivatives Possessing 1,2,3-Triazole-4-carboxamide Moiety as c-Met kinase inhibitors. Bioorg Med Chem, 2014, 22: 6438–6452. (雙通訊, IF=2.951)

[教育背景]

沈陽藥科大學(xué)

本文來源：http://www.zhongzhouzhikong.com/syykdx/yjsds_548360.html